![]() Steensberg and the rest of the management team as we refocus our efforts on advancing our clinical pipeline. “I’m delighted to continue working alongside Dr. Kendall, newly appointed Chief Medical Officer, Zealand Pharma. “It is an honor to take on this role during such an exciting and transformative time for Zealand,” said Dr. We look forward to benefitting even further from his leadership as we approach multiple upcoming clinical and regulatory milestones.” “Since joining our team in 2020, David has provided invaluable expertise, giving strong medical and scientific direction for multiple clinical programs across our pipeline. ![]() Kendall’s expertise will be critical to Zealand in his new role as Chief Medical Officer, particularly as we refocus efforts on advancing our unique research and development pipeline,” said Adam Steensberg, Chief Executive Officer, Zealand Pharma. Kendall most recently served as Senior Global Medical Advisor at Zealand and has more than 35 years of experience in diabetes and metabolic disease, with a broad-based career in research, education, clinical care and the pharmaceutical industry. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of David M. June 2, 20 22 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. Kendall has over 35 years of diabetes and metabolic disease experience including nearly two decades in the pharma industryĬopenhagen, DK and Boston, MA, U.S.Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy.Zealand Pharma Announces Appointment of David M.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |